01.03.2017 • News

Marubeni Buys into Feed Additives Supplier

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

Japanese conglomerate Marubeni Corp has reached agreement to take a 60% stake in Dutch feed additive distributor Orffa International Holding. Financial terms of the transaction were not disclosed.

Orffa sells a large number of feed additives, including Japanese products, to 60 countries worldwide. Its biggest market is Europe, which has a highly developed animal husbandry industry that prioritizes environmental protection and safety – a focus that Marubeni expects will become standard throughout the world in the future.

The Tokyo-headquartered group, which employs 100 people and is also present in the Americas, Middle East and Asia, said it will support the global expansion of Orffa’s business model, particularly in the Asian market, by using Marubeni’s network of agriculture, animal husbandry and fisheries fields.

According to Marubeni, the current global feed additives market, estimated to be worth $20 billion currently, is forecast to continue growing at 4-5% per year as protein demand increases as a result of rising populations in emerging countries and a preference for high-quality products in developed countries.

The Japanese player has a focus on life sciences and said it aims to further expand its business in functional food materials, cosmetic raw materials and other areas that are closely aligned to the feed additives markets.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read